Afatinib - NDSRI's
References
FAQ's
References
- Soyka, Rainer; Rall, Werner; Schnaubelt, Juergen; Sieger, Peter; Kulinna, Christian, Process for preparing amino crotonyl compounds, Boehringer Ingelheim International GmbH, Germany, US8426586B2, April 25, 2013
- Ankalla, Kiran Kumar; Gollapalli, Nageswara Rao, A stability-indicating UPLC method for quantification of Afatinib related substances in pharmaceutical dosage forms, World Journal of Pharmacy and Pharmaceutical Sciences, Volume: 6, Issue: 12, Pages: 1253-1267, 2017
Frequently Asked Questions
How are the impurities formed in Afatinib?
Impurities in Afatinib occur from raw materials, incomplete reaction, degradation during storage, and purification.
Do impurities in Afatinib affect the pharmacokinetics of the drug?
The impurities in Afatinib affect the pharmacokinetics leading to changes in bioavailability, metabolism, and elimination.
Which solvent helps in the analysis of Afatinib impurities?
Methanol is a solvent used in analyzing many impurities in Afatinib.
What are the temperature conditions required to store Afatinib impurities?
Afatinib impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.